MENLO PARK, Calif, Dec. 5, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, will share research with the cell biology community next week that identifies the mechanism of action by which molecular iodine can fight fibrocystic breast condition (FBC)
The data will be shared in a poster presentation titled "The Molecular Mechanism of Action of Molecular Iodine on MCF10A Cells from Fibrocystic Breast Tissue," at the ASCB's Cell Biology 2016 in San Francisco, Tuesday.
Results from the in vitro study indicated that molecular iodine had potent inhibitory effects on cell growth and showed an increase in the death MCF10A cells, a human immortalized mammary epithelial cell line derived from fibrocystic breast tissues. The study also found that molecular iodine had no significant impact on healthy cells.
The study found that molecular iodine can induce cell death by activating caspase-independent apoptosis.
"The administration of molecular iodine to patients with FBC reduces swelling and other FBC symptoms," said Lee P. Shulman MD, Professor of Ob/Gyn at the Feinberg School of Medicine of Northwestern University in Chicago, Illinois. "The results indicate that iodine inhibits proliferation of MCF10A cells in vitro, suggesting a potential mechanism of action for molecular iodine in the treatment of symptoms of FBC.
Iodine supplementation has long been recognized in clinics for the treatment of symptoms experienced by patients with FBC, a condition estimated to affect approximately 50 percent of women. Symptoms of FBC include breast swelling, pain, and tenderness. This study is the first to identify molecular iodine's mechanism of action on fibrocystic breast tissue-derived cells.
BioPharmX, Inc., has developed a novel and proprietary formulation sold as Violet® iodine, which consists of iodide and iodate salts that, when exposed to gastric pH, react to form molecular iodine.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, molecular iodine's effect on inhibiting fibrocystic breast tissue cell growth and promoting the death of MCF10A cells, the lack of impact on healthy cells, and the potential for use of molecular iodine in the treatment of symptoms of FBC. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
SOURCE BioPharmX Corporation